about
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse modelDevelopment and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.Determination of viral tropism by genotyping and phenotyping assays in Brazilian HIV-1-infected patients.Forward Look: Tenth Anniversary of the Human Genome Sequence and 21 Century Postgenomics Global Health - A Close Up on Africa and Women's Health.CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.Individualization of antiretroviral therapy.Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patientsArginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism.HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.CCR5 inhibitors: emergence, success, and challenges.Antiretroviral therapy: effects on orofacial health and health care.Contributions of HIV-1 Nef to immune dysregulation in HIV-infected patients: a therapeutic target?CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.Targeting chemokine receptors for HIV: past, present and future.A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study.
P2860
Q28484915-3D7940A4-7A48-4D39-81BA-AD835DE178C2Q33643626-52EF2112-AC5E-4ACB-9B08-006A35028A17Q34040770-9C614D70-02A3-4570-84C6-B5D8933EB285Q35690458-4F2D00A2-18E2-476E-A51F-02E02E7E3E0AQ35956560-10162E8E-BC6E-48E7-88D4-3A8EC68C431CQ36306935-12DFF88D-7C64-437F-8ED2-BC9EBA982331Q36441423-2F666163-7FA4-4781-8DAD-BF5214E9214BQ36715890-413C95AD-44FF-4E62-925F-87EEE138824CQ37080284-0BCA4F82-641C-4150-87A6-A2D5A61E9DE4Q37525642-A2BA0F6E-2C05-4695-835A-AC14596F1033Q38005459-884B7C97-A0CA-48FB-821D-D23F7CED239DQ38093238-A5A2D7F5-6DC1-4D63-B0D9-EBB0A77D961AQ38130717-B4CA7538-9CB2-45B2-AD6C-411A227C8996Q38803127-D3468F5B-3FE4-4EE2-81A0-A64D5D4CF0ABQ38936482-EBBE4E79-F9A7-4614-B719-C6FBAE763390Q41024442-A604C6C9-0C7A-474B-9793-265330D81CD5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical utility of maraviroc.
@en
Clinical utility of maraviroc.
@nl
type
label
Clinical utility of maraviroc.
@en
Clinical utility of maraviroc.
@nl
prefLabel
Clinical utility of maraviroc.
@en
Clinical utility of maraviroc.
@nl
P2093
P2860
P50
P1476
Clinical utility of maraviroc
@en
P2093
Ana Mariño
Carlos Galera
Celia Miralles
Enrique Ortega
Fernando Dronda
Félix Gutiérrez
Hernando Knobel
Jorge Parra
Jose López-Aldeguer
José A Oteo
P2860
P304
P356
10.2165/11590700-000000000-00000
P577
2011-01-01T00:00:00Z